STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class
From BiotechTV - News · 00:11:01
Show by BiotechTV
He describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like ADHD, MS, and Parkinson's further on down the line. Plus how the acquisition of Avadel has been a fit, and whether he would consider doing additional deals.
More episodes of BiotechTV - News
More episodes
- STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month
- Stifel's Tim Opler on the state of biotech
- STIFEL 2026: REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever
- Stifel's Head of Global Equity Capital Markets Seth Rubin shares his take on the state of biotech and the current environment for companies to raise money
- STIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead
- STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial in human data on its oral PTH19 agonist for hypoparathyroidism in Q1
- STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months
- STIFEL 2026: Cullinan Therapeutics' CEO Nadim Ahmed gives an overview of the progress of the company's T-cell engagers in autoimmune and oncology (and more)
- STIFEL 2026: Compugen has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific
- Stifel Research Analyst Alex Thompson shares his take on the state of the I&I space and highlights a few key companies
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.